[1]
Rahim, N. 2025. Bispecific CAR-T vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed/Refractory Multiple Myeloma. Highlights in Science, Engineering and Technology. 153, (Sept. 2025), 42–47. DOI:https://doi.org/10.54097/wvmnsh51.